BR112016023839A8 - Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptina - Google Patents
Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptinaInfo
- Publication number
- BR112016023839A8 BR112016023839A8 BR112016023839A BR112016023839A BR112016023839A8 BR 112016023839 A8 BR112016023839 A8 BR 112016023839A8 BR 112016023839 A BR112016023839 A BR 112016023839A BR 112016023839 A BR112016023839 A BR 112016023839A BR 112016023839 A8 BR112016023839 A8 BR 112016023839A8
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- sitagliptin
- thannate
- pharmaceutical
- dosage form
- Prior art date
Links
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title abstract 7
- 229960004034 sitagliptin Drugs 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- 239000012450 pharmaceutical intermediate Substances 0.000 title abstract 2
- 229920002253 Tannate Polymers 0.000 abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980641P | 2014-04-17 | 2014-04-17 | |
| PCT/US2015/025504 WO2015160678A1 (en) | 2014-04-17 | 2015-04-13 | Sitagliptin tannate complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016023839A2 BR112016023839A2 (pt) | 2017-08-15 |
| BR112016023839A8 true BR112016023839A8 (pt) | 2023-04-11 |
Family
ID=54324454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016023839A BR112016023839A8 (pt) | 2014-04-17 | 2015-04-13 | Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9833463B2 (https=) |
| EP (1) | EP3131631B1 (https=) |
| JP (1) | JP6523328B2 (https=) |
| KR (1) | KR102351813B1 (https=) |
| CN (1) | CN106456998B (https=) |
| AU (1) | AU2015247921B2 (https=) |
| BR (1) | BR112016023839A8 (https=) |
| CA (1) | CA2945681A1 (https=) |
| ES (1) | ES2932383T3 (https=) |
| MX (1) | MX374598B (https=) |
| RU (1) | RU2696588C2 (https=) |
| WO (1) | WO2015160678A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201818969A (zh) * | 2016-10-19 | 2018-06-01 | 日商帝化製藥股份有限公司 | 在生體內之藥物溶出控制用組成物 |
| US11096890B2 (en) | 2017-09-29 | 2021-08-24 | Merck Sharp & Dohme Corp. | Chewable dosage forms containing sitagliptin and metformin |
| WO2025090920A1 (en) * | 2023-10-25 | 2025-05-01 | Piton Therapeutics, Inc. | Compositions and methods for treating dysfunction of glucose metabolism and/or regulation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US5663415A (en) | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| DE60023492T2 (de) | 1999-05-17 | 2006-07-20 | Novo Nordisk A/S | Glucagon antagonisten/inverse agonisten |
| CA2379604A1 (en) | 1999-09-28 | 2001-04-05 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| US6881741B2 (en) | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
| US6670370B1 (en) | 2001-12-14 | 2003-12-30 | Jame Fine Chemicals, Inc. | Dextromethorphan tannate |
| US20030114535A1 (en) | 2001-12-14 | 2003-06-19 | Jame Fine Chemicals, Inc. | Dextrochlorpheniramine tannate |
| JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| JP2007504230A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態 |
| EP1667524A4 (en) | 2003-09-23 | 2009-01-14 | Merck & Co Inc | NEW CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR |
| US20080227786A1 (en) | 2004-01-16 | 2008-09-18 | Ferlita Russell R | Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor |
| US20050202050A1 (en) * | 2004-03-12 | 2005-09-15 | Kiel Jeffrey S. | Single tank process for preparing tannate liquid and semi-solid dosage forms |
| EP1796671A4 (en) | 2004-09-15 | 2009-01-21 | Merck & Co Inc | AMORPHIC FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL-PEPTIDASE IV HEMMER |
| US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| US20090221592A1 (en) * | 2005-07-25 | 2009-09-03 | Ellison Martha E | Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
| AU2006306420A1 (en) * | 2005-10-25 | 2007-05-03 | Merck Sharp & Dohme Corp. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| JP5356248B2 (ja) | 2006-12-14 | 2013-12-04 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンのタンニン酸塩 |
| JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| EP2218721A1 (en) | 2009-02-11 | 2010-08-18 | LEK Pharmaceuticals d.d. | Novel salts of sitagliptin |
| US9211263B2 (en) * | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
-
2015
- 2015-04-13 KR KR1020167028345A patent/KR102351813B1/ko active Active
- 2015-04-13 ES ES15780045T patent/ES2932383T3/es active Active
- 2015-04-13 US US15/302,211 patent/US9833463B2/en active Active
- 2015-04-13 BR BR112016023839A patent/BR112016023839A8/pt not_active Application Discontinuation
- 2015-04-13 WO PCT/US2015/025504 patent/WO2015160678A1/en not_active Ceased
- 2015-04-13 EP EP15780045.9A patent/EP3131631B1/en active Active
- 2015-04-13 JP JP2016562508A patent/JP6523328B2/ja active Active
- 2015-04-13 MX MX2016013588A patent/MX374598B/es active IP Right Grant
- 2015-04-13 CA CA2945681A patent/CA2945681A1/en not_active Abandoned
- 2015-04-13 CN CN201580020211.4A patent/CN106456998B/zh active Active
- 2015-04-13 RU RU2016144695A patent/RU2696588C2/ru active
- 2015-04-13 AU AU2015247921A patent/AU2015247921B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX374598B (es) | 2025-03-06 |
| ES2932383T3 (es) | 2023-01-18 |
| RU2696588C2 (ru) | 2019-08-05 |
| EP3131631A4 (en) | 2017-11-29 |
| WO2015160678A1 (en) | 2015-10-22 |
| AU2015247921B2 (en) | 2019-07-11 |
| US9833463B2 (en) | 2017-12-05 |
| BR112016023839A2 (pt) | 2017-08-15 |
| RU2016144695A (ru) | 2018-05-21 |
| JP6523328B2 (ja) | 2019-05-29 |
| JP2017511350A (ja) | 2017-04-20 |
| MX2016013588A (es) | 2017-01-26 |
| EP3131631B1 (en) | 2022-11-16 |
| CA2945681A1 (en) | 2015-10-22 |
| AU2015247921A1 (en) | 2016-10-13 |
| EP3131631A1 (en) | 2017-02-22 |
| US20170042922A1 (en) | 2017-02-16 |
| CN106456998B (zh) | 2020-07-28 |
| KR102351813B1 (ko) | 2022-01-18 |
| KR20160145008A (ko) | 2016-12-19 |
| CN106456998A (zh) | 2017-02-22 |
| RU2016144695A3 (https=) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| GT201700033A (es) | Anticuerpos anti tigit | |
| ECSP14013325A (es) | Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr) | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| CL2017001661A1 (es) | Compuestos biciclicos fusionados para el tratamiento de una enfermedad. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| MX383376B (es) | Derivado de un anillo condensado y método de preparación, compuesto intermedio, composición farmacéutica y uso del mismo. | |
| IN2014CH00247A (https=) | ||
| CL2013002908A1 (es) | Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia . | |
| GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
| DK3170005T3 (da) | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer | |
| MX2017007338A (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis. | |
| CL2016002839A1 (es) | Derivados de carboxamida | |
| EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
| EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
| UY36938A (es) | Nuevos compuestos macrocíclicos modificados | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| UY36923A (es) | Nuevos compuestos macrocíclicos de sulfondiimina | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2017012342A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades,. | |
| EA201792234A1 (ru) | Новые соединения пиридиния |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000637-2 PROTOCOLO 870230003440 EM 12/01/2023 16:35. |
|
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |